EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

MicroTech Med (Hangzhou) Co (2235) fair value: what the stock is really worth

As of Sep 24, 2026: fair value of MicroTech Med (Hangzhou) Co HK$4.09, price HK$6.91, upside -40.8%, quality 67 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? Yes
  3. Add to watchlist

Healthcare · HK · Home China · ISIN CNE100004QN6

MM Thin data Sep 24, 2026

MicroTech Med (Hangzhou) Co

2235 · HK

Stretched ValuationStrong overvaluation with only moderate quality.

!Fair value HK$4.09 · Strongly overvalued (−41%)
✓Quality 67/100
!Expensive Growth (revenue 5y +54.4 %/yr)
!Thin margins · 6.1% net margin (TTM)
!Low debt · negative free cash flow
!Mixed vs. peers (6/12)
!Narrow moat 23/100
!Evidence only low, so the estimate is less certain
!Weak on past: 8 out of 100
Watch MicroTech Med (Hangzhou) Co for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

HK$30.75 HK$3.56 Fair Value HK$4.09 Oct 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

59‑month range HK$3.56 – HK$30.75 · fair‑value band HK$3.93 – HK$5.31 · the HK$6.91 price screens above the HK$4.09 fair value. Dashed = 300-day average. As of Sep 24, 2026.

Follow MicroTech Med (Hangzhou) Co in your weekly email

Every Wednesday you see whether MicroTech Med (Hangzhou) Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

MicroTech Medical (Hangzhou) Co., Ltd. provides diabetes management, diabetes treatment, and diabetes monitoring and treatment medical devices in China and internationally.

Show more

MicroTech Medical (Hangzhou) Co., Ltd. provides diabetes management, diabetes treatment, and diabetes monitoring and treatment medical devices in China and internationally. The company offers Equil patch insulin pump systems; AiDEX and LinX continuous glucose monitoring systems; POCT analyzer systems; closed-loop artificial pancreas systems; blood glucose monitoring systems; Exactive Pro blood glucose, blood ketone, and uric acid monitoring system; API open platform; and diabetes digital management software. It also involved in scientific research and technical services; business services; wholesale and retail; manufacturing; and commercials business. MicroTech Medical (Hangzhou) Co., Ltd. was incorporated in 2011 and is headquartered in Hangzhou, the People's Republic of China.

Stock analysis

MicroTech Med (Hangzhou) Co (2235) currently trades at HK$6.91, while our model-based Fair Value estimate is HK$4.09, implying the stock looks roughly 68.9% overvalued today.

Show more

Valuation

Bull case: the DCF Models group reads highest at a median of HK$4.80 per share, and 0 of the 10 models we run sit above the HK$6.91 price.

Bear case: the Multiples group reads lowest at HK$1.70, and 10 of the 10 models stay below the price. Evidence for this calculation is low.

Scenario range: HK$3.93 (bear) to HK$5.31 (bull), the price of HK$6.91 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 67/100 (solid quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

MicroTech Med (Hangzhou) Co reported revenue of 661M CNY in FY2025 versus 151M CNY in FY2021, a compound +44.5%/yr. Reported net income was 40.2M CNY in FY2025.

Key figures

Market cap HK$3.0B (≈ $383M) · P/E ratio 61.0 · P/S ratio 3.71 · EPS (TTM) HK$−0.0100 · Net margin 6.1% · Return on equity 2.0% · Return on assets (EBIT) −2.1% · Operating margin 4.4%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).

What moves the price

The share trades about 17% below its 52-week high and 8% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 5% fair-value upside, at −41%, 2235 screens richer than that median.

Fair Value models

Bear HK$3.93 Fair Value HK$4.09 Bull HK$5.31
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
Owner Earnings HK$4.26 HK$4.80 HK$5.81 76
Residual Income HK$3.29 HK$3.00 HK$2.14 74
Growth-Adj P/E HK$3.25 HK$4.65 HK$6.04 65
All 10 models by family
DCF Models
Owner Earnings HK$4.26 HK$4.80 HK$5.81 76
Earnings-Based
Graham-Dodd HK$0.6800 HK$4.74 HK$6.66 61
Lynch FV HK$2.45 HK$3.50 HK$4.55 59
PEG = 1.0 HK$2.45 HK$3.50 HK$4.55 55
Multiples
P/E Multiple HK$1.65 HK$2.20 HK$2.75 63
P/S Multiple HK$1.28 HK$1.70 HK$2.13 58
P/B Multiple HK$1.28 HK$1.70 HK$2.13 55
Asset-Based
NCAV (Graham) HK$2.51 HK$3.36 HK$5.02 54
Economic Profit
Residual Income HK$3.29 HK$3.00 HK$2.14 74
Growth Earnings
Growth-Adj P/E HK$3.25 HK$4.65 HK$6.04 65

Open the full fair value analysis →

Notify me when 2235 reaches fair value

Put 2235 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 67/100

Of which business quality 65 · Market factors (momentum, volatility) 45

Profitability 24
Margins and returns on capital today
Quality Growth 92
Are margins and returns improving?
Cashflow 15
Earnings quality: real cash, not paper profit
Fin. Strength 100
Balance sheet, leverage, solvency risk
Investment 93
Disciplined investing over empire-building
Low Volatility 80
Calm price path (market factor)
Momentum 37
Price trend over the last 3–12 months (market factor)
52W Momentum 20
Distance to the 52-week high (market factor)
Net Issuance 100
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 58/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+91.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+56.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+54.4%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+52.8%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−160.6% (2019) → −18.1% (2024)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no profitable base year
not computed

2235 screens 69% overvalued. Compare with Abbott Laboratories, →

Compare MicroTech Med (Hangzhou) Co with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 365 stocks

Beats the industry median on 5/11 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 67 · Top 25%
Fair Value upside −41% · Below median
Profitability
Return on equity (TTM) 2% · Above median
Return on assets 0% · Below median
Net margin (TTM) 6% · Above median
Operating margin (TTM) 4% · Below median
Growth and dividend
Revenue growth 113% · Top 25%

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/E (TTM) 61.0× · Priciest 25%
P/B 1.27× · Cheaper than median
P/S (TTM) 3.88× · Pricier than median
EV/EBITDA 92.8× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 10
FUTURE (revenue growth)100 · sector 31
PAST (return on equity)8 · sector 7
HEALTH (low debt)100 · sector 97
DIVIDEND (yield)0 · sector 40

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Abbott Laboratories, ABT $101.07 $74.79 −26%
Medtronic plc MDT $88.64 $65.61 −26%
Stryker Corporation SYK $269.75 $296.73 +10%
Boston Scientific Corporation BSX $44.62 $49.08 +10%
Edwards Lifesciences Corporation EW $86.82 $82.04 −6%
Siemens Healthineers AG SHL €37.21 €35.22 −5%
DexCom, Inc DXCM $87.73 $96.50 +10%
GE HealthCare Technologies Inc GEHC $66.27 $69.62 +5%
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥156.68 ¥172.35 +10%
Koninklijke Philips N.V PHIA €21.85 €15.32 −30%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

MicroTech Med (Hangzhou) Co · Fair Value
HK$4.09 −69%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "MicroTech Med (Hangzhou) Co Fair Value". https://www.fairvalue-calculator.com/stock/2235

Frequently asked questions

Is MicroTech Med (Hangzhou) Co (2235) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of HK$4.09 versus a price of HK$6.91, about −41% upside (overvalued).
What is the fair value of 2235?
Our model-based fair value for MicroTech Med (Hangzhou) Co is HK$4.09 (as of Sep 24, 2026), built from audited fundamentals. The current price: HK$6.91.
What is the quality score of 2235?
MicroTech Med (Hangzhou) Co has a Quality Score of 67/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for MicroTech Med (Hangzhou) Co (2235)?
Our model-based price target is the fair value of HK$4.09 (as of Sep 24, 2026) from 10 valuation models. Cautious scenario HK$3.93, optimistic scenario HK$5.31. It is a calculation from audited fundamentals, not an analyst target.
What is the MicroTech Med (Hangzhou) Co stock forecast for 2026?
Our models put fair value at HK$4.09, about −41% upside versus a price of HK$6.91 (overvalued). Cautious scenario HK$3.93, optimistic scenario HK$5.31. The calculation is refreshed regularly with new filings.
What is the revenue of MicroTech Med (Hangzhou) Co (2235)?
MicroTech Med (Hangzhou) Co reported trailing-twelve-month revenue of about 661M CNY (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of MicroTech Med (Hangzhou) Co (2235)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For MicroTech Med (Hangzhou) Co it is HK$4.09 per share (as of Sep 24, 2026), against a price of HK$6.91. It is the blended result of 10 valuation models (cash flow, earnings, asset, dividend).
Is MicroTech Med (Hangzhou) Co stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 2235 trades above its calculated fair value: price HK$6.91, fair value HK$4.09, a gap of about −41% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 2235?
No. The price is what the market pays today (HK$6.91); the fair value is what the company's own numbers justify (HK$4.09). For MicroTech Med (Hangzhou) Co the two are HK$2.82 per share apart. That gap is exactly why we show both numbers side by side.
How much is MicroTech Med (Hangzhou) Co worth?
The market values MicroTech Med (Hangzhou) Co at about HK$3.0B (market capitalisation, as of Sep 24, 2026). Per share that is HK$6.91; our models calculate a fair value of HK$4.09 per share.
What do the bullish and bearish scenarios say about 2235?
Our models span a range for MicroTech Med (Hangzhou) Co: cautious scenario HK$3.93, base HK$4.09, optimistic HK$5.31 per share (as of Sep 24, 2026, price HK$6.91). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 2235?
MicroTech Med (Hangzhou) Co trades at a price-to-earnings ratio of 61.0 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of HK$4.09 is built from several models across several years. Other multiples: P/B 1.3, P/S 3.9, EV/EBITDA 92.8.
How solid is the balance sheet of MicroTech Med (Hangzhou) Co (2235)?
Balance-sheet figures for MicroTech Med (Hangzhou) Co (as of Sep 24, 2026): return on equity 2.0%. They feed the Quality Score of 67/100, which measures business quality independently of the share price.
How far is 2235 from its 52-week high?
MicroTech Med (Hangzhou) Co trades at HK$6.91, about 17% below its 52-week high of HK$8.36 and 8% above the low of HK$6.38 (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of HK$4.09 is for.
Which stocks are comparable to MicroTech Med (Hangzhou) Co?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is MicroTech Med (Hangzhou) Co stock attractive at the current price?
The data as of Sep 24, 2026: price HK$6.91, calculated fair value HK$4.09 (−41%), Quality Score 67/100, from 10 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 2235 calculated?
We run MicroTech Med (Hangzhou) Co through 10 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of HK$4.09, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 12.7 % above its aggregate fair value. MicroTech Med (Hangzhou) Co itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of MicroTech Med (Hangzhou) Co (2235)?
The closing price on Sep 24, 2026 was HK$6.91. Our model-based fair value is HK$4.09, about −41% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with MicroTech Med (Hangzhou) Co right now?
The price sits above even our optimistic bull case (HK$5.31). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (67/100) and above fair value, neither a clear bargain nor a standout compounder.

Key figures of MicroTech Med (Hangzhou) Co

How large is the market capitalisation of MicroTech Med (Hangzhou) Co (2235)?
The market capitalisation of MicroTech Med (Hangzhou) Co is HK$3.0B (≈ $383M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of MicroTech Med (Hangzhou) Co (2235)?
The price-to-sales ratio of MicroTech Med (Hangzhou) Co is 3.71 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of MicroTech Med (Hangzhou) Co (2235)?
Earnings per share at MicroTech Med (Hangzhou) Co are HK$−0.0100 (price ÷ EPS = P/E 61.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of MicroTech Med (Hangzhou) Co (2235)?
The net margin of MicroTech Med (Hangzhou) Co is 6.1% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of MicroTech Med (Hangzhou) Co (2235)?
The return on equity (ROE) of MicroTech Med (Hangzhou) Co is 2.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of MicroTech Med (Hangzhou) Co (2235)?
On an EBIT basis the return on assets of MicroTech Med (Hangzhou) Co is −2.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of MicroTech Med (Hangzhou) Co (2235)?
The operating margin of MicroTech Med (Hangzhou) Co is 4.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at MicroTech Med (Hangzhou) Co (2235)?
Revenue at MicroTech Med (Hangzhou) Co is growing +113% versus a year earlier (3y avg +56.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does MicroTech Med (Hangzhou) Co (2235) generate?
The free cash flow of MicroTech Med (Hangzhou) Co is −6.1M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does MicroTech Med (Hangzhou) Co (2235) hold?
MicroTech Med (Hangzhou) Co holds more cash than debt, 1.4B CNY net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch MicroTech Med (Hangzhou) Co in the live analysis

One click puts MicroTech Med (Hangzhou) Co on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.